Adeno-associated viruses (AAVs) are a key focus in gene therapy field due to their favorable safety profile, efficiency in delivering genetic material to target cells, and their potential for long-lasting therapeutic effects. However, the primary challenge in AAV gene therapy is the pre-existing immunity in individuals caused by natural exposure to AAVs, which can lead to the immediate neutralization of the therapeutic vector before it reaches its target cells. https://antiviral.creative-diagnostics.com/adeno-associated-virus-aav-neutralizing-antibody-testing.html